Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Philpott

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Gastroenterology|September 22, 2023
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal AdenocarcinomaYuliang Feng, Liuyang Cai, Martin Pook, et al.
Angewandte Chemie (International Ed. in English)|November 16, 2018
Design, Synthesis and Characterization of Covalent KDM5 InhibitorsSaleta Vazquez-Rodriguez, Miranda Wright, Catherine M Rogers, et al.
Blood|March 31, 2021
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomasJames Heward, Lola Konali, Annalisa D'Avola, et al.
Communications Medicine|July 31, 2025
A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleedingChen-Yi Wang, Martin Philpott, Darragh P O'Brien, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Journal of Medicinal Chemistry|September 25, 2019
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin FunctionVincent Fagan, Catrine Johansson, Carina Gileadi, et al.
Cancer Research|November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapySarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
JCI Insight|September 26, 2024
The human milk oligosaccharide 3'sialyllactose reduces low-grade inflammation and atherosclerosis development in miceAriane R Pessentheiner, Nathanael J Spann, Chloe A Autran, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Gastroenterology|September 22, 2023
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal AdenocarcinomaYuliang Feng, Liuyang Cai, Martin Pook, et al.
Angewandte Chemie (International Ed. in English)|November 16, 2018
Design, Synthesis and Characterization of Covalent KDM5 InhibitorsSaleta Vazquez-Rodriguez, Miranda Wright, Catherine M Rogers, et al.
Blood|March 31, 2021
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomasJames Heward, Lola Konali, Annalisa D'Avola, et al.
Communications Medicine|July 31, 2025
A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleedingChen-Yi Wang, Martin Philpott, Darragh P O'Brien, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Journal of Medicinal Chemistry|September 25, 2019
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin FunctionVincent Fagan, Catrine Johansson, Carina Gileadi, et al.
Cancer Research|November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapySarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
JCI Insight|September 26, 2024
The human milk oligosaccharide 3'sialyllactose reduces low-grade inflammation and atherosclerosis development in miceAriane R Pessentheiner, Nathanael J Spann, Chloe A Autran, et al.
Pageof 8